**Attachment 3 - Service Description and Product Requirements**

CONTENTS

**Attachment 3** - Service Description / product requirements 1

INTRODUCTION - executive summary 2

1. THE REQUIREMENT 3

2. AUTHORITY RESPONSIBILITIES 3

3. SUPPLIER RESPONSIBILITIES 3

4. TIMETABLE AND PAYMENTS 3

5. CONTRACT MONITORING 4

6. GENERAL INSTRUCTIONS 4

7. REPRESENTATIVES **4**

8. MEETINGS 4

9. REMEDIES 4

#

**INTRODUCTION - Executive Summary**

* 1. In the event of a pandemic or other health emergency it is likely that medicines supply may be disrupted. Supply disruptions could put an additional burden on the health system. As part of ongoing strategic work to ensure the continuity of medicine supplies and to ensure that supplies of medicines are available within the UK to respond to supply disruptions caused by pandemics or other emergencies, the Secretary of State for Health acting through the Department of Health and Social Care (DHSC) owns an Essential Medicines Buffer Stockpile (EMBS), which was first set up in 2009. The purpose of the stockpile is to have medicines that are routinely used in the NHS, available for release into the UK supply chain in the event of pandemic or other health emergency. The current EMBS (2) contract was finalised in November 2015 and runs for 4 years.

## Following a review of the product list held under EMBS (2), the Authority has determined to conduct a separate procurement exercise to secure additional supplies of both Intravenous Fluids (IV Fluids) and Peritoneal Dialysis Fluids (PD Fluids) to support the EMBS.

## In case of a pandemic or emergency, shortages of IV Fluids and PD Fluids could lead to more hospitalisation and deaths which would put more pressure on the NHS. Some of the medicines in the EMBS (2) need to be administered using IV Fluids.

* 1. An additional benefit of the EMBS is that it allows DHSC to respond to emergencies other than a pandemic. There are other emergencies, health related or not, that like a pandemic have the potential to lead to large scale supply disruptions leading to shortages.
	2. This stock also helps the government to respond to those medicine shortages that are a result of manufacturing or regulatory problems within the medicine supply chain, and therefore helps to ensure that patient needs can be met.
1. **THE REQUIREMENT**

## Deliverable 1: To procure IV Fluids and PD Fluids at a stock level equivalent to 3 months of normal NHS usage for the entire NHS to include the devolved administrations of Scotland, Wales and Northern Ireland.

## Deliverable 2: Stock holding and rotation of IV Fluids and PD Fluids on the supplier site as ‘Consignment Stock’.

## The estimated cost for both the IV Fluids and PD Fluids (both product and storage costs) is estimated at a maximum £32m (ex VAT) for the total contract duration of 19 months (with option to extend for a further 12 month period at the Authority’s discretion) the remaining stock is resold to the supplier at a pre-agreed price.

## The Authority’s expectation is that any Contract(s) awarded as a result of this Procurement will expire (or terminate) on or around October 2019, when the contracts for EMBS 3 (the successor to EMBS 2), which will be the subject of a separate procurement exercise commences. EMBS 3 will include the supply and storage of IV Fluids and PD Fluids.

## Potential Providers are able to bid for one or more product lines across the two product ranges e.g. lots. You are able to bid for part of the volume of one product line. One product line may be awarded to one or more potential providers.

1. **AUTHORITY RESPONSIBILITIES**

The Authority will appoint a project manager to manage the appointed provider.

1. **SUPPLIER RESPONSIBILITIES**

The Supplier shall appoint a Contract Manager to oversee the work and liaise with / report to the Authority’s project manager.

The Supplier shall keep the Authority informed of progress and at least one appropriate representative will be available for weekly updates with Authority. Draft reports will be shared early with Authority during development and key findings will be communicated as they arise. The Supplier shall perform quality assurance of all aspects of the programme.

1. **TIMETABLE AND PAYMENTS**

The Authority shall make payments for goods in line with clause 13 - ‘Price, Payment and Invoicing’ detailed within ‘Attachment 4 - Conditions of Contract for Goods and Services’

1. **CONTRACT MONITORING**

To be confirmed on award of the Contract(s).

**6. GENERAL INSTRUCTIONS**

Potential Providers will be required to provide all the information as requested within the Tender documentation. Any supporting documents (e.g. implementation plans etc.) will need to be clearly referenced back to the appropriate section.

**7. RESPRESENTATIVES**

7.1 Name of Authority's Contract Representative(s):

 Mohammed Sohail - (Senior Accountant - PPRS)

7.2 Name of Supplier's Representative(s): see below

Tenderer to complete in response document(s)

**8. MEETINGS**

8.1 Frequency of contract management meetings: to be confirmed

8.2 Location of contract management meetings: TBC

**9. REMEDIES**

9.1 Remedies for poor performance: In line with the Contract.

**PRODUCT LIST DETAILS**

|  |  |
| --- | --- |
| **LOT 1 - INTRAVENOUS FLUIDS** |   |
| Name | **3 Month Volume** |
| Compound sodium lactate\_1 litre\_iv infusion1 |  1,856,463  |
| Compound sodium lactate\_500ml\_iv infusion1 |  339,303  |
| Glucose/sodium chloride\_4%/0.18% 1 litre\_iv infusion1 |  79,697  |
| Glucose/sodium chloride\_5%/0.45%- 500mL\_iv infusion1 |  26,278  |
| Glucose 5% / Sodium chloride 0.9%- 500mL\_iv infusion1 |  52,986  |
| Glucose\_10%- 500mL\_iv infusion1 |  117,245  |
| Glucose\_50%- 500mL\_iv infusion1 |  10,592  |
| Glucose\_5%- 1 litre\_iv infusion1 |  137,458  |
| Glucose 5%- 500ml\_iv infusion1 |  123,058  |
| Glucose 5%- 100ml\_iv infusion1 |  357,350  |
| Sodium chloride\_0.9%- 1 litre\_iv infusion1 |  1,962,323  |
| Potassium chloride 0.3% (potassium 40mmol/1litre) / Sodium chloride 0.9% 1 litre\_iv infusion1 |  141,215  |
| Potassium chloride 3% (potassium 40mmol/100ml) / Sodium chloride 0.9% 100ml\_iv infusion1 |  78,835  |

|  |  |
| --- | --- |
| **LOT 2 - PERITONEAL DIALYSIS FLUIDS** |   |
| Name | **3 month volume** |
| PD Fluids -BAL. 1.5%, 1.25CA, 2.0L, W2 or direct equivalent |  27,017  |
| PD Fluids -BAL. 1.5%, 1.25CA, 5.0L, W2 APD or direct equivalent |  14,573  |
| PD Fluids -BAL. 2.3%, 1.25CA, 2.0L, W2 or direct equivalent |  6,187  |
| PD Fluids -BAL. 2.3%, 1.25CA, 5.0L, W2 APD or direct equivalent |  3,801  |
| PD Fluids -CAPD 17- 2000ML, 9-LANGUAGE RC or direct equivalent |  26,432  |
| PD Fluids -CAPD 17- 5000ML, 9 LAN. RC APD or direct equivalent |  13,473  |
| PD Fluids -CAPD 19 - 2000ML, 9-LANGUA RC or direct equivalent |  6,140  |
| PD Fluids -CAPD 19 - 5000ML, 9 LAN. RC APD or direct equivalent |  4,242  |
| PD Fluids -CAPD 17 - 1500ML,9-LANG. RC or direct equivalent |  6,711  |
| PD Fluids -DNL PD4 1.36% - 1.5L/2L, SY2 TB or direct equivalent |  19,274  |
| PD Fluids -DNL PD4 1.36% - 2.5L/3L, SY2 TB or direct equivalent |  19,274  |
| PD Fluids -DNL PD4 1.36% - 2.5L/5L, SY2 SB or direct equivalent |  17,008  |
| PD Fluids -DNL PD4 1.36% - 2L/2L, SY2 TB or direct equivalent |  146,721  |
| PD Fluids -DNL PD4 1.36% - 5L/5L, SY2 SB or direct equivalent |  228,758  |
| PD Fluids -DNL PD4 2.27% - 1.5L/2L, SY2 TB or direct equivalent |  4,539  |
| PD Fluids -DNL PD4 2.27% - 2.5L/5L, SY2 SB or direct equivalent |  3,905  |
| PD Fluids -DNL PD4 2.27% - 2L/2L, SY2 TB or direct equivalent |  3,905  |
| PD Fluids -DNL PD4 2.27% - 5L/5L, SY2 SB or direct equivalent |  3,905  |
| PD Fluids -DNL PD4 3.86% - 5L/5L, SY2 SB or direct equivalent |  6,497  |
| PD Fluids -EXTRANEAL - 2.5L/3L, SY2 SB or direct equivalent |  18,044  |
| PD Fluids -EXTRANEAL - 2.5L/3L, SY2 TB or direct equivalent |  3,876  |
| PD Fluids -EXTRANEAL - 2L/2L, SY2 SB or direct equivalent |  128,068  |
| PD Fluids -EXTRANEAL - 2L/2L, SY2 TB or direct equivalent |  76,156  |
| PD Fluids -NUTRINEAL PD4 - 2.5L, SY2 SB or direct equivalent |  13,582  |
| PD Fluids -NUTRINEAL PD4 - 2L/2L, SY2 TB or direct equivalent |  9,989  |
| PD Fluids -PHYSIO 35 1.36% - 2.5L, SY2 SB or direct equivalent |  8,084  |
| PD Fluids -PHYSIO 35 1.36% - 2L, SY2 TB or direct equivalent |  2,675  |
| PD Fluids -PHYSIO 35 2.27% - 2.5L, SY2 SB or direct equivalent |  4,863  |
| PD Fluids -PHYSIO 40 1.36% - 2.5L, SY2 SB or direct equivalent |  70,985  |
| PD Fluids -PHYSIO 40 1.36% - 2.5L, SY2 TB or direct equivalent |  8,458  |
| PD Fluids -PHYSIO 40 1.36% - 2L, SY2 TB or direct equivalent |  63,583  |
| PD Fluids -PHYSIO 40 1.36% - 5L, SB CF or direct equivalent |  22,513  |
| PD Fluids -PHYSIO 40 2,27% - 2.5L, SY2 SB or direct equivalent |  31,915  |
| PD Fluids -PHYSIO 40 2.27% - 2.5L, SY2 TB or direct equivalent |  5,402  |
| PD Fluids -PHYSIO 40 2.27% - 5L, SB CF or direct equivalent |  18,795  |
| PD Fluids -PHYSIONEAL 40 2.27% - 2L TB 4 X 2000 ML or direct equivalent |  21,654  |

Potential Providers are also required to detail their breakdown of proposed Storage Costs as detailed within Attachment 8 - Offer Schedule

Technical details that Potential Providers are to be supply are as follows - please refer to Attachment 8 - Offer Schedule (tab 3) for the full detailed requirements:

* Potential Providers shall provide details that evidence capability to be able to store product(s) within the range specified in the Summary of Product Characteristics of the product(s).
* Potential Providers shall provide details that outline the security in place at the site(s) where product(s) is to be stored under the Contract.
* Potential Providers shall provide details of the warehouse system(s) in place at the site(s) where product(s) is to be stored under the Contract.
* Potential Providers shall provide details of the security measures in place to protect data relating to the products(s) where the products(s) are to be stored under the contract.
* Potential Providers shall provide a copy of their Business Continuity Plan which shall include, but is not restricted to, the manufacturing process of the products, Stock Building phase, Storage Services and Authorised Release.

Storage Details to be supplied are as follows - please refer to Attachment 8 - Offer Schedule (tab 5):

* Name of storage location.
* Address of storage location.
* Wholesale Distribution Authorisation (H) number.
* Wholesale Distribution Authorisation (H) date.
* Wholesale Distribution Authorisation (H) licence number / site number.
* Name of Responsible Person (at organisation and proposed storage site).
* Name of Medicines to be stored at site (ambient / chilled / controlled conditions).